<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations of relapsing polychondritis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations of relapsing polychondritis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations of relapsing polychondritis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marcela A Ferrada, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Hoyt Buckner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 24, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsing polychondritis (RPC) is an immune-mediated condition associated with inflammation in cartilaginous structures and other tissues throughout the body, particularly the ears, nose, eyes, joints, and respiratory tract. Other organs that can be involved include the vasculature, inner ear, central nervous system, and skin. A high percentage of patients with a genetic disease described in 2020 called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome have a clinical diagnosis of RPC [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The clinical features and course of RPC vary considerably from patient to patient. Subtle, early manifestations often remain unrecognized for prolonged periods. As a result, the diagnosis is frequently obtained only after the emergence of characteristic manifestations such as auricular inflammation, saddle-nose deformity, or other features of cartilage destruction. No known clinical or laboratory measures predict the expression of specific disease manifestations or the overall disease course.
        </p>
        <p>
         The clinical features of RPC are reviewed here. The pathogenesis, pathology, diagnosis, and treatment of RPC are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5604.html" rel="external">
          "Etiology and pathogenesis of relapsing polychondritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5621.html" rel="external">
          "Pathology of relapsing polychondritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5609.html" rel="external">
          "Diagnostic evaluation of relapsing polychondritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5587.html" rel="external">
          "Treatment of relapsing polychondritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapsing polychondritis (RPC) is a rare disease that appears to occur among individuals of all races and age groups. Males and females are affected equally, but much about the epidemiology of RPC remains unknown because of the relatively small number of affected patients. RPC is most prevalent in White individuals. The annual incidence has been estimated at 0.71, 2.0, and 3.5 per million persons from population studies in the United Kingdom, Hungary, and Minnesota, respectively [
         <a href="#rid2">
          2-4
         </a>
         ]. Onset is most likely between the ages of 40 and 60, although RPC can occur in childhood  (
         <a class="graphic graphic_figure graphicRef78633" href="/z/d/graphic/78633.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         RPC is not a familial disease, although studies indicate that some genetic contribution to susceptibility is likely. One case report suggested the possibility of placental transmission [
         <a href="#rid6">
          6
         </a>
         ]. However, no other cases of this occurrence are confirmed, and the reported association may be secondary to chance or a confluence of other circumstances. In general, cases suggesting placental transmission are exceptionally rare, even if the mother may be experiencing active multisystem disease [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H194591783">
         <span class="h2">
          Major features and clinical course
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features of relapsing polychondritis (RPC) vary in severity and duration, both at presentation and throughout the course of the illness. Although auricular involvement is the most common feature, it can happen later in the disease course. Recognizing the pattern of organ involvement other than ear chondritis can help with early diagnosis. Other anatomic areas and organs that can be involved include the costal cartilage, eyes, nose, airways, heart, vascular system, skin, musculoskeletal system, kidney, and nervous system  (
         <a class="graphic graphic_table graphicRef76071" href="/z/d/graphic/76071.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Vascular disease is presumed to be the cause of many of the primary manifestations of RPC [
         <a href="#rid7">
          7-9
         </a>
         ]. Nonspecific constitutional symptoms such as fatigue, malaise, and fever may also be seen, and RPC can present as a fever of unknown origin.
        </p>
        <p>
         Clinical phenotypes have been described in several studies, including a retrospective cluster analysis of 142 patients with RPC from a single center [
         <a href="#rid10">
          10
         </a>
         ]. This study found a group with primary hematologic disorders, especially myelodysplastic syndrome (MDS), which had the worst prognosis. A second group with laryngotracheal or bronchial involvement experienced more infections and intensive care unit (ICU) admissions but surprisingly did not have a worse outcome than the third cluster of patients with mild disease. This improved prognosis compared with earlier series is likely related to better antiinflammatory therapies and respiratory care [
         <a href="#rid10">
          10
         </a>
         ]. Another study that included 73 patients prospectively used latent class analysis and found three subgroups of patients with RPC based on clinical manifestations [
         <a href="#rid11">
          11
         </a>
         ]. Type I RPC was characterized by significant cartilaginous involvement and damage including ear, nose, and upper airway; type II RPC was defined by mainly lower airway involvement; and type III RPC included mainly patients who did not have significant cartilaginous damage. All types of RPC were found to have significant disability and require use of disease-modifying antirheumatic drugs (DMARDs), highlighting the refractory nature of the disease and associated morbidity. Notably, both studies identified a respiratory subgroup.
        </p>
        <p>
         It is difficult to predict the clinical course of RPC because there is a marked inter-patient variability. The patterns that may be seen include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Episodic disease activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Smoldering disease with ever-changing severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Refractory disease with ongoing disease activity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A fulminant downhill course resulting in death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A relatively benign course that is free of clinically evident major organ involvement and is easily managed. It is not possible to estimate the prevalence of this self-limited pattern, since it is likely that many of these cases are not diagnosed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Ear involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unilateral or bilateral external ear inflammation is the most common presenting feature of RPC, seen in approximately 40 percent of patients; it eventually appears in nearly 90 percent of patients. However, this clinical feature can present late in the disease course. Some patients may have subtle ear manifestations that can be missed  (
         <a class="graphic graphic_picture graphicRef54829" href="/z/d/graphic/54829.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The onset of auricular disease may be acute or subacute and develops without evident cause [
         <a href="#rid12">
          12
         </a>
         ]. In some cases, it can be triggered by minimal trauma. Pain and tenderness can be pronounced. The initial presentation or the first several disease flares are usually misdiagnosed as infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The affected auricles can assume a patchy or diffuse, violaceous, erythematous appearance, in most cases sparing the non-cartilaginous ear lobes  (
         <a class="graphic graphic_picture graphicRef81482" href="/z/d/graphic/81482.html" rel="external">
          picture 2
         </a>
         ). However, some patients can have inflammation that includes the earlobes; in addition, inflammation can involve the external auditory canal. Inflammation restricted to the tragus and conchal bowl has been reported, as has extension of the inflammation to the face [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Auricular inflammation may subside within days or persist for several weeks. It can encroach on the external auditory meatus, compromise hearing, and/or extend to the retroauricular soft tissues.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sustained or recurrent episodes of inflammation can permanently alter the structural integrity of cartilage, resulting in a "floppy eared" or "cauliflower" appearance  (
         <a class="graphic graphic_picture graphicRef87692" href="/z/d/graphic/87692.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         Although relatively uncommon at presentation, auditory and/or vestibular involvement appears acutely or insidiously at some point, each occurring in about one-third of patients with RPC [
         <a href="#rid14">
          14,15
         </a>
         ]. Impaired hearing, tinnitus, or vertigo can result either from inner ear inflammation associated with chondritis-induced destruction of the Eustachian tube, endolymphatic hydrops, or sensorineural hearing loss or from vasculitis of the internal auditory artery or its cochlear branch. (See
         <a class="medical medical_review" href="/z/d/html/6844.html" rel="external">
          "Etiology of hearing loss in adults", section on 'Inner ear causes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Eye involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ocular disease is a frequent problem in RPC, affecting about 20 percent of patients at presentation and up to approximately 60 percent at some time during the course of the disease [
         <a href="#rid2">
          2,16-18
         </a>
         ]. Forms of ocular involvement in RPC include [
         <a href="#rid16">
          16,17,19,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Episcleritis – Episcleritis is often noted incidentally when other organ manifestations of RPC are prominent. (See
         <a class="medical medical_review" href="/z/d/html/5610.html" rel="external">
          "Episcleritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Scleritis – Scleritis in RPC is similar to the scleritis associated with rheumatoid arthritis and can range from milder forms such as diffuse anterior scleritis  (
         <a class="graphic graphic_picture graphicRef55940" href="/z/d/graphic/55940.html" rel="external">
          picture 4
         </a>
         ) to the more severe forms of necrotizing anterior or posterior scleritis  (
         <a class="graphic graphic_picture graphicRef81029" href="/z/d/graphic/81029.html" rel="external">
          picture 5
         </a>
         ). In RPC, it tends to be more necrotizing, bilateral, and recurrent compared with other systemic etiologies of scleritis [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5599.html" rel="external">
          "Clinical manifestations and diagnosis of scleritis", section on 'Scleritis subtypes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inflammation within the sclera can lead to a bluish or dark discoloration, caused by scleral thinning that permits visualization of the underlying choroid  (
         <a class="graphic graphic_picture graphicRef52035" href="/z/d/graphic/52035.html" rel="external">
          picture 6
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Peripheral ulcerative keratitis – Patients with severe scleritis may also be at risk for necrotizing inflammation of the cornea. Peripheral ulcerative keratitis can lead rapidly to visual loss  (
         <a class="graphic graphic_picture graphicRef63438" href="/z/d/graphic/63438.html" rel="external">
          picture 7
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">
          "Clinical manifestations and diagnosis of rheumatoid vasculitis", section on 'Ocular disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uveitis – Uveal tract disease may occur in either the anterior or posterior portion of the eye in RPC. (See
         <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">
          "Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Salmon patch conjunctival lesion – The occurrence of a "salmon patch" lesion within the conjunctiva has been reported in RPC [
         <a href="#rid22">
          22
         </a>
         ]. The histopathology of this lesion in RPC is benign reactive lymphoid hyperplasia. Salmon patch conjunctival lesions have also been reported in sarcoidosis, multiple myeloma, lymphoma, leukemia, and amyloidosis [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proptosis – Unilateral or bilateral proptosis may be caused by inflammation of the choroid, posterior elements of the globe, or other periocular tissues. In this disease manifestation, RPC resembles granulomatosis with polyangiitis. Clinical features accompanying proptosis include chemosis, ophthalmoplegia, and/or lid edema. A pseudotumor of the orbit which fails to respond to antiinflammatory therapy should raise concern for a possible lymphoma [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Nose involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms of nasal cartilage inflammation include stuffiness; crusting; rhinorrhea; epistaxis; pain, redness, and swelling of the bridge of the nose; and/or nose pressure. Nasal chondritis is present in approximately 20 percent of patients at presentation and 60 percent over the course of the illness [
         <a href="#rid2">
          2
         </a>
         ]. The sense of smell may be compromised, with resultant hypogeusia. Cartilage destruction associated with sustained or recurrent episodes of inflammation can result in a characteristic saddle nose deformity, which is seen in about 10 percent of patients at presentation and 25 percent during the disease course  (
         <a class="graphic graphic_picture graphicRef80564" href="/z/d/graphic/80564.html" rel="external">
          picture 8
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Large airway involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large airway disease that includes the larynx, trachea, and bronchi can begin in a subtle fashion that, if undiagnosed for a prolonged period of time, sometimes evolves into life-threatening disease due to subglottic stenosis and/or tracheobronchomalacia. Laryngotracheal disease occurs in more than half of patients and laryngotracheal stricture in nearly one-quarter [
         <a href="#rid2">
          2
         </a>
         ]. The critical management issue is diagnosing and treating large airway disease promptly, before irreversible damage and loss of tissue integrity occurs. Symptomatic airway disease may be a forme fruste of RPC that occurs in the absence of other discernible features of this disorder, making the recognition of airway involvement imperative for decreasing morbidity in these patients [
         <a href="#rid25">
          25-28
         </a>
         ].
        </p>
        <p>
         The clinical manifestations of laryngotracheobronchial disease vary with the degree and extent of airway involvement [
         <a href="#rid29">
          29
         </a>
         ]. The early stages of lower airway disease can be asymptomatic or in some cases misdiagnosed as refractory asthma [
         <a href="#rid30">
          30
         </a>
         ]. Symptoms of large airway disease include hoarseness, aphonia, wheezing, inspiratory stridor, a nonproductive cough, and dyspnea. Tenacious upper respiratory tract secretions are a problem in some patients. Tenderness may be noted over the thyroid cartilage and anterior tracheal region.
        </p>
        <p>
         Other manifestations of large airway disease include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glottic, subglottic, laryngeal, or tracheobronchial inflammation, with luminal encroachment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of structural cartilaginous support, resulting in "dynamic" laryngeal collapse during forced inspiration and/or tracheal collapse during expiration. Obstructive sleep apnea caused by partial airway collapse can occur [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Necrotizing sialometaplasia of the larynx, which may be misdiagnosed as a malignancy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fibrosis-induced luminal contracture.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary infection, which can result from obstruction of distal airways.
        </p>
        <p>
        </p>
        <p>
         If the diagnosis is made late in the course, tracheal or subglottic narrowing may warrant immediate tracheostomy. However, intratracheal manipulations cause additional inflammation, and, if present, more distal airway compromise can diminish the efficacy of proximal correction by tracheostomy. Optimal therapy is unclear in these settings.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Joint involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Involvement of the parasternal joints (the sternoclavicular, costochondral, and manubriosternal articulations) is typical of RPC. Arthritis is seen at presentation in up to a third of patients, and peripheral joint involvement eventually occurs in approximately 50 to 70 percent. There is no predilection for either large or small joints  (
         <a class="graphic graphic_table graphicRef76071" href="/z/d/graphic/76071.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid2">
          2,33-36
         </a>
         ].
        </p>
        <p>
         In peripheral joints, the processes may differ from the destructive cartilaginous inflammation found in the ears, nose, eyes, and large airways. In particular, peripheral joint disease in RPC is usually nonerosive unless associated with an underlying arthritis such as rheumatoid arthritis. Tenosynovitis is also a common manifestation in patients with RPC.
        </p>
        <p>
         The peripheral joint disease has the following additional characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both large and small peripheral joints may be affected, with distributions that range from monoarticular disease to oligoarticular involvement to polyarthritis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymmetric arthritis is not unusual.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthralgia can occur in the absence of objective evidence of inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Synovial fluid aspirates are usually noninflammatory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The arthritis may resolve spontaneously over days to weeks and can be responsive to antiinflammatory treatment with just nonsteroidal antiinflammatory drugs (NSAIDs); however, in other patients, it can be difficult to treat.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The asymptomatic interval between flares is variable in length.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On occasion, vertebral involvement may be observed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Heart involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically significant aortic or mitral valvular disease occurs in approximately 10 percent of patients. Less frequent cardiac manifestations of RPC include pericarditis, heart block, and myocardial infarction due to coronary arteritis.
        </p>
        <p>
         A review of 440 patients with RPC found the following prevalence of valvular disease [
         <a href="#rid37">
          37
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated aortic regurgitation: 7.7 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated mitral valve regurgitation: 1.8 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combined valvular regurgitation: 1.6 percent
        </p>
        <p>
        </p>
        <p>
         Aortic regurgitation can result from the destruction of valvular cusps, aortic ring dilatation, or dilatation or thickening of the aortic root. (See
         <a class="medical medical_review" href="/z/d/html/8159.html" rel="external">
          "Clinical manifestations and diagnosis of chronic aortic regurgitation in adults"
         </a>
         .)
        </p>
        <p>
         Valvular disease may appear within months of the onset of other RPC symptoms or may be delayed for more than a decade [
         <a href="#rid38">
          38
         </a>
         ]. Progression of the disease is often insidious; as a result, echocardiography should be performed periodically to assess for valvular thickening or regurgitation [
         <a href="#rid39">
          39
         </a>
         ]. The clinician must be alert to changes in the intensity or character of an existing murmur or to the development of a new murmur. (See
         <a class="medical medical_review" href="/z/d/html/1078.html" rel="external">
          "Auscultation of cardiac murmurs in adults"
         </a>
         .)
        </p>
        <p>
         The interval from RPC onset to the need for operative intervention ranged from five months to 21 years (mean 6.5 years) in one review [
         <a href="#rid37">
          37
         </a>
         ]. Surgery was performed on average one year after the diagnosis of valvular regurgitation. During the first four postoperative years, reoperation was required in approximately 25 percent of patients because of either early valvular leaks or aneurysm formation secondary to tissue friability. Fifty-three percent of patients who required surgery ultimately died of a cardiovascular event during this same period [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8160.html" rel="external">
          "Natural history and management of chronic aortic regurgitation in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">
          "Chronic primary mitral regurgitation: Indications for intervention"
         </a>
         .)
        </p>
        <p>
         In addition, one case of chondritis complicated by rapidly fatal giant cell myocarditis and myositis has been reported [
         <a href="#rid40">
          40
         </a>
         ]. This rare form of cardiomyopathy has also been associated with other autoimmune diseases. With more systematic screening and improved echocardiographic technology, up to 22 percent of patients in a large 2016 single-center series were estimated to possibly have a cardiac valvulopathy [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Kidney involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of kidney disease in RPC remains unclear and likely very rare. Kidney disease, as determined by biopsy or the presence of hematuria and/or proteinuria, was present in 29 of 129 patients (23 percent) seen at the Mayo Clinic between 1943 and 1984 [
         <a href="#rid41">
          41
         </a>
         ]. At that time, there was no specific test to diagnose patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV); due to the similarities between patients with RPC and AAV, it remains unclear how many patients in this study would likely have been reclassified as having AAV rather than RPC by use of subsequently developed criteria.
        </p>
        <p>
         The most frequent kidney lesions observed by biopsy are mesangial expansion with cellular proliferation and segmental necrotizing glomerulonephritis [
         <a href="#rid41">
          41
         </a>
         ]. Tubulointerstitial disease and immunoglobulin A (IgA) nephropathy have also been reported [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Nervous system involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In unusual cases, RPC presents with primarily neurologic manifestations. Neurologic involvement is presumed to be due to vasculitis, although this has seldom been documented [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         The most common neurologic features are cranial neuropathies of the second, sixth, seventh, and eighth nerves [
         <a href="#rid44">
          44
         </a>
         ]. A variety of other neurologic complications of RPC have been reported, often in association with underlying diseases: hemiplegia, seizures, organic brain syndrome, dementia [
         <a href="#rid45">
          45
         </a>
         ], myelitis, peripheral neuropathy, aseptic meningitis, lymphocytic meningoencephalitis [
         <a href="#rid46">
          46
         </a>
         ], rhomboencephalitis [
         <a href="#rid47">
          47
         </a>
         ], limbic encephalitis [
         <a href="#rid48">
          48
         </a>
         ], and pachymeningitis related to polyangiitis with granulomatosis [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Skin disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of skin findings can occur in RPC. However, none are pathognomonic for RPC, and some are nonspecific  (
         <a class="graphic graphic_table graphicRef97539" href="/z/d/graphic/97539.html" rel="external">
          table 2
         </a>
         ). A retrospective analysis of 200 patients with RPC followed at a single center reported the following observations [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin lesions were noted in 36 percent of patients, including an array of clinical findings usually associated with vasculitis: aphthous ulcers, purpura, papules, nodules, pustules, ulcerations, superficial thrombophlebitis, livedo reticularis, and distal necrosis. Neutrophilic dermatosis (Sweet syndrome) is observed in RPC related to MDS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic examination of biopsied lesions demonstrated vasculitis, cutaneous vessel thrombosis, septal panniculitis, and neutrophilic dermatosis.
        </p>
        <p>
        </p>
        <p>
         Dermatologic manifestations were the presenting symptom in 12 percent of patients. There was no correlation between skin features and sex, age at RPC onset, or sites of cartilaginous or major organ involvement. The frequency of skin lesions was significantly higher among patients with concurrent MDS.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Gastrointestinal tract involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal involvement in RPC is infrequent unless there are concurrent manifestations of systemic vasculitis. There have been sporadic reports of coexisting ulcerative colitis, Crohn disease, systemic sclerosis, and diabetic autonomic dysfunction. At times, dysphagia can result from esophageal manometric abnormalities similar to those of systemic sclerosis [
         <a href="#rid51">
          51
         </a>
         ]. Rare associations with sclerosing cholangitis and primary biliary cholangitis (previously referred to as primary biliary cirrhosis) and pneumatosis cystoides have also been reported.
        </p>
        <p>
         Not all gastrointestinal symptoms are due to gastrointestinal disease. As an example, odynophagia and dysphagia can result from epiglottitis, thyroid, laryngeal, or tracheal cartilage inflammation.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Miscellaneous
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unifocal or multifocal abscesses characterized by deep, sterile, antibiotic resistant lesions have been described in RPC [
         <a href="#rid52">
          52
         </a>
         ]. These lesions typically respond to glucocorticoids. Involvement may potentially include abdominal lymph nodes, liver, spleen, pancreas, lung, and brain.
        </p>
        <p class="headingAnchor" id="H2525279123">
         <span class="h1">
          LABORATORY STUDIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory abnormalities can be seen in patients with relapsing polychondritis (RPC) but are nonspecific. Some of these changes reflect the presence of active inflammatory disease and may be helpful adjuncts in evaluation and management. In some instances, patients with RPC can have normal inflammatory markers despite objective findings of inflammation on physical exam  (
         <a class="graphic graphic_table graphicRef67505" href="/z/d/graphic/67505.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/5609.html" rel="external">
          "Diagnostic evaluation of relapsing polychondritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5587.html" rel="external">
          "Treatment of relapsing polychondritis"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elevations in the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) level and a modest leukocytosis or thrombocytosis are associated with clinical and subclinical disease activity. However, these parameters are not informative as indices of disease progression, which often results from insidiously advancing fibrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anemia is usually present at some point during the course of illness. It is typically normocytic and normochromic, consistent with anemia of chronic disease (see
         <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">
          "Anemia of chronic disease/anemia of inflammation"
         </a>
         ). Coombs reactive hemolysis is unusual.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilia occurs in about 10 percent of patients. Its significance is unclear since it does not appear to correlate with disease activity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H801657896">
         <span class="h2">
          Nonspecific autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serologic studies have revealed antinuclear antibodies (ANA) in percentages varying from 22 to 66 percent of RPC patients [
         <a href="#rid53">
          53
         </a>
         ]. A homogeneous or speckled pattern is usually evident by immunofluorescence, but the specificity of the responsible antigens is unknown. Antibodies to native deoxyribonucleic acid (DNA), Sm, U1 RNP, and Ro/La are
         <strong>
          not
         </strong>
         characteristic of RPC itself.
        </p>
        <p>
         Other serologic abnormalities including rheumatoid factor (in 16 percent of cases), a false positive serologic test for syphilis, and antiphospholipid antibodies (positive in one of eight reported cases, manifested clinically by acute thrombosis) can also occur [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H169069861">
         <span class="h2">
          Antineutrophil cytoplasmic antibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several features of RPC which suggest the potential for an increased frequency of antineutrophil cytoplasmic antibodies (ANCA). (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ANCA is prevalent in granulomatosis with polyangiitis (GPA), which shares a number of features with RPC such as laryngotracheal bronchial disease, necrotizing glomerulonephritis, episcleritis, saddle nose deformity, and auricular chondritis. The presence of an ANCA in this setting suggests the diagnosis of GPA, not RPC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Fourteen percent of patients with RPC have clinically evident vasculitis that is not GPA or MPA [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasculitis is likely operative in the pathogenesis of specific organ system involvement in many RPC patients.
        </p>
        <p>
        </p>
        <p>
         There is discordance in the literature regarding the role of ANCA in the vasculitis of RPC. One report, for example, found low titer ANCA (as assessed by immunofluorescence) in 8 of 23 patients with RPC [
         <a href="#rid55">
          55
         </a>
         ]. Three had a C-ANCA pattern (diffuse granular cytoplasmic staining), and five had P-ANCA reactivity (perinuclear staining)  (
         <a class="graphic graphic_picture graphicRef66748 graphicRef78968" href="/z/d/graphic/66748.html" rel="external">
          picture 9A-B
         </a>
         ). The specificity of these antibodies was examined by ELISA. None of the C-ANCA responders were positive for serine proteinase 3, the dominant antigen responsible for this pattern in GPA. Four of the five positive P-ANCA patients were reactive with myeloperoxidase, the antigen associated with P-ANCA in GPA and microscopic polyarteritis. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
         A subsequent study demonstrated ANCA reactivity in three of six patients in whom RPC appeared in conjunction with a systemic necrotizing form of vasculitis (GPA or microscopic polyarteritis) [
         <a href="#rid56">
          56
         </a>
         ]. Thus, although ANCA may be detected in patients thought to have RPC, when present, its relevance and relationship to associated vasculitis require further analysis. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1264195606">
         <span class="h2">
          Other studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total hemolytic complement and C3 and C4 levels are usually normal in RPC [
         <a href="#rid33">
          33
         </a>
         ]. Occasional elevations in complement levels probably reflect an acute phase response. The prevalence and significance of circulating immune complexes have not been systematically evaluated. Using varying methodologies, immune complexes have been identified in 15 of 35 reported cases (43 percent) [
         <a href="#rid57">
          57
         </a>
         ]. Cryoglobulins appear to occur less frequently, being detected in 7 of 32 cases (22 percent) compiled from the literature.
        </p>
        <p>
         Transient increases may occur in immunoglobulin G (IgG), IgA, or IgE levels. Serum protein electrophoresis may show nonspecific abnormalities, such as a decrease in albumin and elevations in the alpha-1 and gamma globulin regions.
        </p>
        <p>
         An adequate laboratory gauge defining active cartilage catabolism and, thus, a means of monitoring disease activity are lacking in RPC. Studies have investigated the feasibility of measurement of serum content of noncollagenous cartilage-specific adhesive glycoproteins and serum matrillin-1 fragments to reflect active inflammation [
         <a href="#rid58">
          58-60
         </a>
         ]. Urine levels of a type II collagen specific neoepitope generated by specific interstitial collagenase CII cleavage are being investigated, but the clinical usefulness is uncertain [
         <a href="#rid61">
          61
         </a>
         ]. Serum cartilage oligomeric matrix protein (COMP) is also being investigated as a potential biomarker of disease activity [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Collagen II antibodies can be positive in patients with RPC, but are not specific to this disorder [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p>
         Although analysis of cerebrospinal fluid may be normal in the presence of clinical evidence of central nervous system involvement, there is usually a pleocytosis with a predominance of lymphocytes, a protein content that is either normal or slightly elevated, and a normal glucose concentration [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          COEXISTENT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to one-third of patients with relapsing polychondritis (RPC) present with a recognizable form of systemic vasculitis, a connective tissue disease or other autoimmune disorder, or a malignant or premalignant condition  (
         <a class="graphic graphic_table graphicRef97540" href="/z/d/graphic/97540.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid2">
          2,50,65
         </a>
         ]. The intercurrent disease may precede RPC by months to years, occur after the diagnosis of RPC, or present simultaneously with RPC. In the last setting, RPC symptoms and signs may bring the patient to medical attention. (See
         <a class="local">
          'Systemic vasculitis'
         </a>
         below and
         <a class="local">
          'Other autoimmune diseases'
         </a>
         below and
         <a class="local">
          'Malignancy'
         </a>
         below and
         <a class="local">
          'Immunodeficiency'
         </a>
         below.)
        </p>
        <p>
         Whether the association of RPC with other diseases is coincidental or representative of a shared genetic predisposition to different disorders is not known. One study that examined the immunogenetics of RPC found that human leukocyte antigen (HLA)-DR4 was significantly more common in patients with RPC than in healthy controls (60 versus 26 percent) [
         <a href="#rid66">
          66
         </a>
         ]. This parallels the established observation of DR4 positivity in RA. However, no predominance of any of the DRB1*04 subtype alleles was seen in the polychondritis group in contrast to the clear association of DRB1*0401 and DRB1*0404 in patients with RA. (See
         <a class="medical medical_review" href="/z/d/html/7487.html" rel="external">
          "HLA and other susceptibility genes in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Systemic vasculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasculitis is proven histologically in approximately 14 to 25 percent of patients with RPC [
         <a href="#rid67">
          67
         </a>
         ]. Features of vasculitis may appear at any stage of the disease, either simultaneous with or independent of other manifestations, and may be indolent or fulminant.
        </p>
        <p>
         Vasculitis may involve large vessels, including the aorta and its branches to the head, neck, and extremities; medium-sized vessels such as the coronary, hepatic, mesenteric and renal arteries; and small vessels, including the post-capillary venules [
         <a href="#rid50">
          50
         </a>
         ]. Death can result from rupture of aneurysms of the ascending, thoracic, and abdominal aorta and the subclavian arteries [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         The presence of systemic vasculitis is generally associated with a poor prognosis. In a series of 112 patients from the Mayo Clinic, the five-year survival rate was 45 percent, similar to that of polyarteritis alone [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         Among patients with RPC, vasculitis may be an integral part of the primary disease process or may exist in a concurrent pathologically distinct form. Virtually all of the major types of vasculitis have been reported in association with RPC. Some of these simultaneous occurrences are probably related to chance alone. However, for others, the co-occurrence of these two diseases probably represents common predisposition to autoimmune disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortitis [
         <a href="#rid70">
          70
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyarteritis nodosa [
         <a href="#rid71">
          71
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Behçet syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin A vasculitis (Henoch-Schönlein purpura)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cogan syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thromboangiitis obliterans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous leukocytoclastic angiitis
        </p>
        <p>
        </p>
        <p>
         An overlap syndrome of RPC and Behçet syndrome has been described in which patients present with features resembling both conditions. This syndrome is termed the "MAGIC" syndrome, an acronym for mouth and genital ulcers with inflamed cartilage [
         <a href="#rid72">
          72,73
         </a>
         ]. These patients can have distinct manifestations including aortitis, more eye inflammatory disease, Raynaud phenomenon, and thromboembolic events [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Other autoimmune diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPC can occur in patients with other connective tissue diseases such as rheumatoid arthritis, systemic lupus erythematosus, and the syndrome of remitting, seronegative, symmetrical synovitis with pitting edema (RS3PE) [
         <a href="#rid74">
          74
         </a>
         ]. Organ-specific autoimmune diseases such as Graves' disease, Hashimoto's thyroiditis, ulcerative colitis, idiopathic hypoparathyroidism, and Crohn disease have also been reported in association with RPC.
        </p>
        <p>
         A case of RPC associated with hepatitis C virus (HCV) infection with mixed cryoglobulinemia has been reported [
         <a href="#rid75">
          75
         </a>
         ]. This case was remarkable for the fact that treatment of the underlying HCV with interferon gamma and
         <a class="drug drug_general" data-topicid="9860" href="/z/d/drug information/9860.html" rel="external">
          ribavirin
         </a>
         resulted in an undetectable HCV load and resolution of the RPC symptoms.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Malignancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, myelodysplastic syndrome (MDS) has been described in association with RPC [
         <a href="#rid10">
          10,50,76
         </a>
         ]. In a series of 200 patients with RPC, MDS was diagnosed in 22 (11 percent) [
         <a href="#rid50">
          50
         </a>
         ]. MDS can occur before, simultaneously with, or after RPC. The etiology of this conglomeration of symptoms and bone marrow involvement is likely the genetically described disease called VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. (See
         <a class="medical medical_review" href="/z/d/html/4492.html" rel="external">
          "Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'VEXAS syndrome'
         </a>
         .)
        </p>
        <p>
         Isolated instances of Hodgkin lymphoma, non-Hodgkin lymphoma, and carcinoma of a variety of types have been described [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Immunodeficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         RPC has been reported rarely in association with common variable immunodeficiency (CVID), with descriptions in both a child and an adult with CVID [
         <a href="#rid78">
          78,79
         </a>
         ]. In patients with human immunodeficiency virus (HIV) infection, RPC may occur during immune restoration with antiretroviral therapy [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few reports have evaluated the effect of pregnancy on relapsing polychondritis (RPC) and vice versa. This issue was addressed in a study of 11 females of childbearing age with RPC [
         <a href="#rid81">
          81
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Of 24 pregnancies, RPC remained stable during pregnancy in 16, entered remission in one, and flared during seven.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When combined with previously published case reports, the onset of RPC appeared to occur during pregnancy in 4 of 15 patients. The mean time of disease onset in these four patients was at 20 weeks of gestation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal loss was disproportionately high compared with pregnancies in healthy females (3 of 24 pregnancies).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Features of cartilaginous inflammation and other manifestations of RPC were not found in the mothers' offspring.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relapsing polychondritis (RPC) is a rare immune-mediated condition associated with systemic inflammation with a predilection for the involvement of cartilaginous structures within such organs as the ears, nose, eyes, joints, and respiratory tract  (
         <a class="graphic graphic_table graphicRef76071" href="/z/d/graphic/76071.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unilateral or bilateral external ear inflammation that characteristically spares the earlobe is typical of the ear involvement of RPC, but ear chondritis can be subtle. (See
         <a class="local">
          'Ear involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RPC can cause a number of ocular lesions, including episcleritis, scleritis, and orbital pseudotumor. (See
         <a class="local">
          'Eye involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cartilaginous inflammation in RPC may cause pain over the bridge of the nose and may eventually lead to nasal bridge collapse (saddle nose deformity). (See
         <a class="local">
          'Nose involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large airway disease in RPC can affect the larynx, trachea, and bronchi and sometimes causes significant obstructive respiratory disease, the sleep apnea syndrome, and post-obstructive pneumonias. (See
         <a class="local">
          'Large airway involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Musculoskeletal involvement in RPC can assume many patterns, including tenosynovitis and arthritis that can be mono-, oligo-, or polyarticular, and are usually nonerosive. (See
         <a class="local">
          'Joint involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aortic and/or mitral regurgitation caused by inflammation of the cartilaginous components of the valve can lead to the need for valve replacement. (See
         <a class="local">
          'Heart involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A variety of skin findings can occur in RPC and affect more than one-third of patients, but none are pathognomonic  (
         <a class="graphic graphic_table graphicRef97539" href="/z/d/graphic/97539.html" rel="external">
          table 2
         </a>
         ). Skin lesions may include aphthous ulcers, purpura, papules, nodules, pustules, ulcerations, superficial thrombophlebitis, livedo reticularis, distal necrosis, and neutrophilic dermatosis. (See
         <a class="local">
          'Skin disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately one-third of cases occur in association with another recognizable condition, particularly systemic vasculitis, connective tissue diseases, or malignancy  (
         <a class="graphic graphic_table graphicRef97540" href="/z/d/graphic/97540.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Coexistent disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3236101295">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Clement J Michet, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Beck DB, Ferrada MA, Sikora KA, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020; 383:2628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent PD, Michet CJ Jr, Luthra HS. Relapsing polychondritis. Curr Opin Rheumatol 2004; 16:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazra N, Dregan A, Charlton J, et al. Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study. Rheumatology (Oxford) 2015; 54:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horváth A, Páll N, Molnár K, et al. A nationwide study of the epidemiology of relapsing polychondritis. Clin Epidemiol 2016; 8:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knipp S, Bier H, Horneff G, et al. Relapsing polychondritis in childhood--case report and short review. Rheumatol Int 2000; 19:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gimovsky ML, Nishiyama M. Relapsing polychondritis in pregnancy: a case report and review. Am J Obstet Gynecol 1989; 161:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esdaile J, Hawkins D, Gold P, et al. Vascular involvement in relapsing polychondritis. Can Med Assoc J 1977; 116:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michet CJ. Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am 1990; 16:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selim AG, Fulford LG, Mohiaddin RH, Sheppard MN. Active aortitis in relapsing polychondritis. J Clin Pathol 2001; 54:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dion J, Costedoat-Chalumeau N, Sène D, et al. Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients. Arthritis Rheumatol 2016; 68:2992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrada M, Rimland CA, Quinn K, et al. Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study. Arthritis Rheumatol 2020; 72:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coppola M, Yealy DM. Relapsing polychondritis: an unusual cause of painful auricular swelling. Ann Emerg Med 1992; 21:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan JH, Ahmed I. A case of relapsing polychondritis involving the tragal and the conchal bowl areas with sparing of the helix and the antihelix. J Am Acad Dermatol 1999; 41:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cody DT, Sones DA. Relapsing polychondritis: audiovestibular manifestations. Laryngoscope 1971; 81:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark LJ, Wakeel RA, Ormerod AD. Relapsing polychondritis--two cases with tracheal stenosis and inner ear involvement. J Laryngol Otol 1992; 106:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaak BL, Liesegang TJ, Michet CJ Jr. Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986; 93:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology 1995; 102:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukuda K, Mizobuchi T, Nakajima I, et al. Ocular Involvement in Relapsing Polychondritis. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu EN, Jurkunas U, Rubin PA, et al. Obliterative microangiopathy presenting as chronic conjunctivitis in a patient with relapsing polychondritis. Cornea 2006; 25:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo JH, Chodosh J, Dana R. Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis. Semin Ophthalmol 2011; 26:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sainz-de-la-Maza M, Molina N, Gonzalez-Gonzalez LA, et al. Scleritis associated with relapsing polychondritis. Br J Ophthalmol 2016; 100:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tucker SM, Linberg JV, Doshi HM. Relapsing polychondritis, another cause for a "salmon patch". Ann Ophthalmol 1993; 25:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rofail M, Lee LR, Whitehead K. Conjunctival benign reactive lymphoid hyperplasia associated with myopic scleral thinning. Clin Exp Ophthalmol 2005; 33:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lichauco JJ, Lauer S, Shigemitsu HH, et al. Orbital mucosa-associated lymphoid tissue (MALT)-type lymphoma in a patient with relapsing polychondritis. Arthritis Rheum 2001; 44:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheffield E, Corrin B. Fatal bronchial stenosis due to isolated relapsing chondritis. Histopathology 1992; 20:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsunezuka Y, Sato H, Shimizu H. Tracheobronchial involvement in relapsing polychondritis. Respiration 2000; 67:320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rafeq S, Trentham D, Ernst A. Pulmonary manifestations of relapsing polychondritis. Clin Chest Med 2010; 31:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki S, Ikegami A, Hirota Y, Ikusaka M. Fever and cough without pulmonary abnormalities on CT: relapsing polychondritis restricted to the airways. Lancet 2015; 385:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Montmollin N, Dusser D, Lorut C, et al. Tracheobronchial involvement of relapsing polychondritis. Autoimmun Rev 2019; 18:102353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubey S, Gelder C, Pink G, et al. Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre. ERJ Open Res 2021; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riha RL, Douglas NJ. Obstructive sleep apnoea/hypopnoea as the initial presentation of relapsing polychondritis. Int J Clin Pract 2004; 58:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenig BM. Necrotizing sialometaplasia of the larynx. A report of two cases and a review of the literature. Am J Clin Pathol 1995; 103:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Hanlan M, McAdam LP, Bluestone R, Pearson CM. The arthropathy of relapsing polychrondritis. Arthritis Rheum 1976; 19:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsa A, Expinosa A, Cuesta M, et al. Joint symptoms in relapsing polychondritis. Clin Exp Rheumatol 1995; 13:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gergely P Jr, Poór G. Relapsing polychondritis. Best Pract Res Clin Rheumatol 2004; 18:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew SD, Battafarano DF, Morris MJ. Relapsing polychondritis in the Department of Defense population and review of the literature. Semin Arthritis Rheum 2012; 42:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang-Lazdunski L, Hvass U, Paillole C, et al. Cardiac valve replacement in relapsing polychondritis. A review. J Heart Valve Dis 1995; 4:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall DA, Jackson R, Rae AP, Capell HA. Early aortic valve cusp rupture in relapsing polychondritis. Ann Rheum Dis 1992; 51:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buckley LM, Ades PA. Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis. Arthritis Rheum 1992; 35:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe M, Suzuki H, Ara T, et al. Relapsing polychondritis complicated by giant cell myocarditis and myositis. Intern Med 2013; 52:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang-Miller A, Okamura M, Torres VE, et al. Renal involvement in relapsing polychondritis. Medicine (Baltimore) 1987; 66:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalal BI, Wallace AC, Slinger RP. IgA nephropathy in relapsing polychondritis. Pathology 1988; 20:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massry GG, Chung SM, Selhorst JB. Optic neuropathy, headache, and diplopia with MRI suggestive of cerebral arteritis in relapsing polychondritis. J Neuroophthalmol 1995; 15:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundaram MB, Rajput AH. Nervous system complications of relapsing polychondritis. Neurology 1983; 33:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erten-Lyons D, Oken B, Woltjer RL, Quinn J. Relapsing polychondritis: an uncommon cause of dementia. J Neurol Neurosurg Psychiatry 2008; 79:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanslik T, Wechsler B, Piette JC, et al. Central nervous system involvement in relapsing polychondritis. Clin Exp Rheumatol 1994; 12:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasserfallen JB, Schaller MD. Unusual rhombencephalitis in relapsing polychondritis. Ann Rheum Dis 1992; 51:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohta Y, Nagano I, Niiya D, et al. Nonparaneoplastic limbic encephalitis with relapsing polychondritis. J Neurol Sci 2004; 220:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cañas CA, Díaz-Martínez JC, Tobón GJ. Combination of hypertrophic pachymeningitis, PR3-ANCA-positive vasculitis, and relapsing polychondritis. J Rheumatol 2011; 38:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francès C, el Rassi R, Laporte JL, et al. Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center. Medicine (Baltimore) 2001; 80:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levesque H, Kerleau JM, Ducrotte P, et al. [Esophageal involvement in atrophic polychondritis]. Presse Med 1990; 19:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André MF, Piette JC, Kémény JL, et al. Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature. Medicine (Baltimore) 2007; 86:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piette JC, El-Rassi R, Amoura Z. Antinuclear antibodies in relapsing polychondritis. Ann Rheum Dis 1999; 58:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balsa-Criado A, Gonzalez-Hernandez T, Cuesta MV, et al. Lupus anticoagulant in relapsing polychondritis. J Rheumatol 1990; 17:1426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papo T, Piette JC, Le Thi Huong Du, et al. Antineutrophil cytoplasmic antibodies in polychondritis. Ann Rheum Dis 1993; 52:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handrock K, Gross WL. Relapsing polychondritis as a secondary phenomenon of primary systemic vasculitis. Ann Rheum Dis 1993; 52:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foidart JM, Abe S, Martin GR, et al. Antibodies to type II collagen in relapsing polychondritis. N Engl J Med 1978; 299:1203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxne T, Heinegård D. Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis. Arthritis Rheum 1989; 32:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saxne T, Heinegård D. Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis. Arthritis Rheum 1995; 38:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makiguchi T, Koarai A, Inoue C, et al. A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining. BMC Rheumatol 2020; 4:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraus VB, Stabler T, Le ET, et al. Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis. Arthritis Rheum 2003; 48:2942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempta Lekpa F, Piette JC, Bastuji-Garin S, et al. Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. Clin Exp Rheumatol 2010; 28:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo Y, Bolek EC, Quinn KA, et al. A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome. Semin Arthritis Rheum 2022; 52:151924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tajiri M, Tominaga M, Kinoshita T, et al. Clinical Characteristics of Relapsing Polychondritis: A Report of 8 Cases in Japan. Kurume Med J 2019; 65:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Letko E, Zafirakis P, Baltatzis S, et al. Relapsing polychondritis: a clinical review. Semin Arthritis Rheum 2002; 31:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeuner M, Straub RH, Rauh G, et al. Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients. J Rheumatol 1997; 24:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barzegar C, Vrtovsnik F, Devars JF, et al. Vasculitis with mesangial IgA deposits complicating relapsing polychondritis. Clin Exp Rheumatol 2002; 20:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriano PR, Alonso DR, Baltaxe HA, et al. Multiple aortic aneurysms in relapsing polychondritis. Am J Cardiol 1976; 37:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michet CJ Jr, McKenna CH, Luthra HS, O'Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986; 104:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Besnerais M, Arnaud L, Boutémy J, et al. Aortic involvement in relapsing polychondritis. Joint Bone Spine 2018; 85:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillefert JF, De Wazières B, Meignan F. Orchitis: an unusual feature in relapsing polychondritis. J Rheumatol 1994; 21:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firestein GS, Gruber HE, Weisman MH, et al. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease. Am J Med 1985; 79:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orme RL, Nordlund JJ, Barich L, Brown T. The MAGIC syndrome (mouth and genital ulcers with inflamed cartilage). Arch Dermatol 1990; 126:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manganelli P, Delsante G, Bianchi G, et al. Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis. Clin Rheumatol 2001; 20:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrera I, Concha R, Molina EG, et al. Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia. Semin Arthritis Rheum 2004; 33:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebbar M, Brouillard M, Wattel E, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995; 9:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yanagi T, Matsumura T, Kamekura R, et al. Relapsing polychondritis and malignant lymphoma: is polychondritis paraneoplastic? Arch Dermatol 2007; 143:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaca NE, Aksu G, Yildiz B, et al. Relapsing polychondritis in a child with common variable immunodeficiency. Int J Dermatol 2009; 48:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gavrilova T, Capitle E. A case of relapsing polychondritis and hypogammaglobulinemia. Ann Allergy Asthma Immunol 2013; 111:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolev JC, Maurer TA, Reddy SG, et al. Relapsing polychondritis in HIV-infected patients: a report of two cases. J Am Acad Dermatol 2004; 51:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papo T, Wechsler B, Bletry O, et al. Pregnancy in relapsing polychondritis: twenty-five pregnancies in eleven patients. Arthritis Rheum 1997; 40:1245.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5606 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33108101" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14673390" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26187053" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Incidence and mortality of relapsing polychondritis in the UK: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27418855" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A nationwide study of the epidemiology of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11063294" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Relapsing polychondritis in childhood--case report and short review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2669489" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Relapsing polychondritis in pregnancy: a case report and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/870159" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Vascular involvement in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2189160" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Vasculitis and relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11684729" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Active aortitis in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27331771" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Relapsing Polychondritis Can Be Characterized by Three Different Clinical Phenotypes: Analysis of a Recent Series of 142 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32249511" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1539895" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relapsing polychondritis: an unusual cause of painful auricular swelling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10426914" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A case of relapsing polychondritis involving the tragal and the conchal bowl areas with sparing of the helix and the antihelix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5315141" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Relapsing polychondritis: audiovestibular manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1431531" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Relapsing polychondritis--two cases with tracheal stenosis and inner ear involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3523358" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Ocular and systemic findings in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7724185" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Scleritis associated with systemic vasculitic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34768492" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ocular Involvement in Relapsing Polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16783155" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Obliterative microangiopathy presenting as chronic conjunctivitis in a patient with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21958172" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Relapsing polychondritis: systemic and ocular manifestations, differential diagnosis, management, and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26888976" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Scleritis associated with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8304692" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Relapsing polychondritis, another cause for a "salmon patch".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15670084" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Conjunctival benign reactive lymphoid hyperplasia associated with myopic scleral thinning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11465724" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Orbital mucosa-associated lymphoid tissue (MALT)-type lymphoma in a patient with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1587497" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Fatal bronchial stenosis due to isolated relapsing chondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10867603" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Tracheobronchial involvement in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20692543" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pulmonary manifestations of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592904" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fever and cough without pulmonary abnormalities on CT: relapsing polychondritis restricted to the airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31323366" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tracheobronchial involvement of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33614776" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Respiratory subtype of relapsing polychondritis frequently presents as difficult asthma: a descriptive study of respiratory involvement in relapsing polychondritis with 13 patients from a single UK centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14994981" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Obstructive sleep apnoea/hypopnoea as the initial presentation of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7741108" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Necrotizing sialometaplasia of the larynx. A report of two cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1259793" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The arthropathy of relapsing polychrondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7586772" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Joint symptoms in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15454129" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22417894" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Relapsing polychondritis in the Department of Defense population and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7655680" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cardiac valve replacement in relapsing polychondritis. A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1575597" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Early aortic valve cusp rupture in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1622420" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23774555" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Relapsing polychondritis complicated by giant cell myocarditis and myositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3574118" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Renal involvement in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3287308" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : IgA nephropathy in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8574363" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optic neuropathy, headache, and diplopia with MRI suggestive of cerebral arteritis in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6682200" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nervous system complications of relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18208859" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Relapsing polychondritis: an uncommon cause of dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7842537" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Central nervous system involvement in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1444642" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Unusual rhombencephalitis in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15140611" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Nonparaneoplastic limbic encephalitis with relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21532066" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Combination of hypertrophic pachymeningitis, PR3-ANCA-positive vasculitis, and relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11388093" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Dermatologic manifestations of relapsing polychondritis. A study of 200 cases at a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2141167" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : [Esophageal involvement in atrophic polychondritis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17505254" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aseptic abscesses: a study of 30 patients with or without inflammatory bowel disease and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577373" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Antinuclear antibodies in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2123935" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Lupus anticoagulant in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8323388" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Antineutrophil cytoplasmic antibodies in polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8311544" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Relapsing polychondritis as a secondary phenomenon of primary systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/714080" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antibodies to type II collagen in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2775318" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Involvement of nonarticular cartilage, as demonstrated by release of a cartilage-specific protein, in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7848324" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Serum concentrations of two cartilage matrix proteins reflecting different aspects of cartilage turnover in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32016169" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14558101" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Urinary type II collagen neoepitope as an outcome measure for relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20810035" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34972595" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A prospective observational cohort study and systematic review of 40 patients with mouth and genital ulcers with inflamed cartilage (MAGIC) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30853688" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Clinical Characteristics of Relapsing Polychondritis: A Report of 8 Cases in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12077711" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Relapsing polychondritis: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9002018" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Relapsing polychondritis: clinical and immunogenetic analysis of 62 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11892718" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Vasculitis with mesangial IgA deposits complicating relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1274873" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Multiple aortic aneurysms in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3484422" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Relapsing polychondritis. Survival and predictive role of early disease manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28528280" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Aortic involvement in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7966098" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Orchitis: an unusual feature in relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4014306" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome. Five patients with features of relapsing polychondritis and Behçet's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2360844" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The MAGIC syndrome (mouth and genital ulcers with inflamed cartilage).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11346226" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15190524" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7723411" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Association of myelodysplastic syndrome and relapsing polychondritis: further evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17224547" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Relapsing polychondritis and malignant lymphoma: is polychondritis paraneoplastic?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19416387" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Relapsing polychondritis in a child with common variable immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23886240" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A case of relapsing polychondritis and hypogammaglobulinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15583607" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Relapsing polychondritis in HIV-infected patients: a report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9214424" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Pregnancy in relapsing polychondritis: twenty-five pregnancies in eleven patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
